{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.2","upperLimit":"27.5","value":"6.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Progression-free survival measures the length of time a patient with cancer does not experience disease progression or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"paclitaxel, gemcitabine, and oxaliplatin:\n\n1. Paclitaxel 170 mg/m2 IV d 1 14 days\n2. Gemcitabine 800 mg/m2 IV d 1 14 days\n3. Oxaliplatin 100 mg/m2 IV d 1 14 days","id":"OG000","title":"Paclitaxel, Gemcitabine, and Oxaliplatin"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Through study completion, about 9 years","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}